Key Points
- MBX CEO P. Kent Hawryluk bought 18,500 shares on March 13 at an average price of $28.41, spending $525,585 and increasing his stake to 486,777 shares (about $13.83M), a 3.95% rise in his position.
- Shares moved higher after the disclosure, opening at $29.80 (up 6.4%); the company has a $1.42B market cap, a negative P/E of -12.37, a 12‑month range of $4.81–$44.89, and recently beat EPS estimates ($-0.49 vs. -0.64).
- Institutional and analyst sentiment is mixed but generally positive: large funds like Wellington and Deep Track have materially increased holdings, and the consensus rating is "Moderate Buy" with an average price target of $51.56 despite some sell opinions.
MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) CEO P. Kent Hawryluk acquired 18,500 shares of the company's stock in a transaction on Friday, March 13th. The shares were purchased at an average cost of $28.41 per share, with a total value of $525,585.00. Following the completion of the acquisition, the chief executive officer directly owned 486,777 shares in the company, valued at approximately $13,829,334.57. The trade was a 3.95% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
MBX Biosciences Stock Up 6.4%
MBX stock opened at $29.80 on Tuesday. MBX Biosciences, Inc. has a twelve month low of $4.81 and a twelve month high of $44.89. The company has a market cap of $1.42 billion, a P/E ratio of -12.37 and a beta of 1.07. The business's fifty day moving average is $35.58 and its 200-day moving average is $26.80.
MBX Biosciences (NASDAQ:MBX - Get Free Report) last issued its earnings results on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.15.
Institutional Trading of MBX Biosciences
Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its holdings in shares of MBX Biosciences by 112.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,823,336 shares of the company's stock worth $84,408,000 after buying an additional 2,556,708 shares during the period. Braidwell LP acquired a new stake in MBX Biosciences during the fourth quarter worth approximately $32,127,000. Deep Track Capital LP lifted its position in MBX Biosciences by 43.9% during the third quarter. Deep Track Capital LP now owns 3,150,000 shares of the company's stock worth $55,125,000 after acquiring an additional 961,408 shares during the last quarter. Eventide Asset Management LLC bought a new stake in shares of MBX Biosciences during the fourth quarter worth approximately $28,071,000. Finally, Franklin Resources Inc. boosted its holdings in shares of MBX Biosciences by 164.2% during the third quarter. Franklin Resources Inc. now owns 1,307,288 shares of the company's stock worth $22,878,000 after acquiring an additional 812,436 shares during the period.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the stock. Truist Financial set a $50.00 price target on shares of MBX Biosciences in a research note on Monday, March 9th. The Goldman Sachs Group started coverage on shares of MBX Biosciences in a research report on Thursday, December 4th. They issued a "sell" rating and a $18.00 price objective on the stock. Stifel Nicolaus increased their target price on shares of MBX Biosciences from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Friday, December 19th. Guggenheim raised their target price on shares of MBX Biosciences from $77.00 to $88.00 and gave the company a "buy" rating in a research report on Friday, January 16th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of MBX Biosciences in a research note on Thursday, January 22nd. Ten analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $51.56.
Check Out Our Latest Analysis on MBX
MBX Biosciences Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
